IMGT Corporation Limited Logo

IMGT Corporation Limited

Develops a drug delivery platform using ultrasound and nanotech for oncology.

456570 | KO

Overview

Corporate Details

ISIN(s):
KR7456570001
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 돌마로 172, 성남시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

IMGT Corporation Limited is a clinical-stage biotechnology company specializing in the development of a proprietary drug delivery platform for intractable diseases. Founded in 2010, the company's core technology integrates focused ultrasound with nanotechnology-based medicines to enhance the targeted delivery of therapeutic agents, including gene therapies and immunotherapy solutions. This innovative approach is designed to overcome biological barriers, enabling drugs to more effectively penetrate cancer cells. IMGT's development pipeline includes ultrasonic medical devices and a focus on oncology, with clinical trials underway for treatments such as pancreatic cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-04 00:00
Report Publication Announcement
기업설명회(IR)개최결과
Korean 6.6 KB
2025-05-26 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2025-05-13 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 145.3 KB
2025-05-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-13 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 14.8 KB
2025-05-12 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 102.6 KB
2025-04-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 71.2 KB
2025-04-25 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 113.9 KB
2025-04-25 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제3자배정 유상증자_우선주)
Korean 5.3 KB
2025-04-25 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제3자배정 유상증자)
Korean 5.2 KB
2025-04-21 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 108.1 KB
2025-04-14 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 94.0 KB
2025-04-11 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 89.7 KB
2025-04-07 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 393.7 KB
2025-03-31 00:00
Audit Report / Information
감사보고서제출
Korean 10.5 KB

Automate Your Workflow. Get a real-time feed of all IMGT Corporation Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IMGT Corporation Limited

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IMGT Corporation Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

VALIRX PLC Logo
Advancing oncology & women's health therapeutics and offering preclinical research services.
United Kingdom
VAL
VALUE GOLF Inc. Logo
A golf services hub offering reservations, solo player bookings, e-commerce, lessons, and tours.
Japan
3931
Value HR Co., Ltd. Logo
Offers a health management platform and consulting for corporate health insurance societies in Japan.
Japan
6078
Global OTA for curated tours & experiences, focusing on travel to and from Japan.
Japan
7048
A South Korean travel company offering global tour packages, flights, hotels, and corporate travel.
South Korea
094850
Virax Biolabs Group Ltd Logo
Specializes in T-cell immunity tests and diagnostics for profiling viral disease responses.
United States of America
VRAX
VisionSys AI Inc Logo
Develops AI-powered brain-computer interfaces for the healthcare and biotech sectors.
United States of America
VSA
Vivesto Logo
Develops and licenses novel cancer therapies for humans and animals using proprietary drug delivery.
Sweden
VIVE
Vor Biopharma Inc. Logo
Clinical-stage biotech developing next-gen medicines that target the root cause of autoimmune disease.
United States of America
VOR
Voronoi, Inc. Logo
Develops selective kinase inhibitors and targeted protein degraders for precision oncology.
South Korea
310210

Talk to a Data Expert

Have a question? We'll get back to you promptly.